Cidara Therapeutics, Inc. (NASDAQ:CDTX) major shareholder Target N. V. Biotech acquired 60,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were purchased at an average price of $7.57 per share, with a total value of $454,200.00. Following the transaction, the insider now owns 2,295,272 shares in the company, valued at approximately $17,375,209.04. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Cidara Therapeutics, Inc. (NASDAQ CDTX) opened at $7.85 on Friday. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.16. Cidara Therapeutics, Inc. has a twelve month low of $5.60 and a twelve month high of $11.75.
Cidara Therapeutics (NASDAQ:CDTX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.94) by $0.21. analysts expect that Cidara Therapeutics, Inc. will post -3.31 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2017/11/18/target-n-v-biotech-acquires-60000-shares-of-cidara-therapeutics-inc-cdtx-stock.html.
CDTX has been the subject of a number of analyst reports. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 10th. WBB Securities upgraded shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Zacks Investment Research downgraded shares of Cidara Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine downgraded shares of Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, HC Wainwright upped their price objective on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $13.39.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
What are top analysts saying about Cidara Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cidara Therapeutics Inc. and related companies.